These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 9505993)
1. Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate. Kovarik JM; Mueller EA; Richard F; Tetzloff W J Clin Pharmacol; 1997 Nov; 37(11):1009-14. PubMed ID: 9505993 [TBL] [Abstract][Full Text] [Related]
2. Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics. Mueller EA; Kovarik JM; Uresin Y; Preisig-Flückiger SS; Hensel S; Lücker PW; Holt B J Clin Pharmacol; 1997 Nov; 37(11):1001-8. PubMed ID: 9505992 [TBL] [Abstract][Full Text] [Related]
3. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. Lush RM; Meadows B; Fojo AT; Kalafsky G; Smith HT; Bates S; Figg WD J Clin Pharmacol; 1997 Feb; 37(2):123-8. PubMed ID: 9055138 [TBL] [Abstract][Full Text] [Related]
4. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237 [TBL] [Abstract][Full Text] [Related]
5. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473 [TBL] [Abstract][Full Text] [Related]
6. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. Kovarik JM; Mueller EA; van Bree JB; Tetzloff W; Kutz K J Pharm Sci; 1994 Mar; 83(3):444-6. PubMed ID: 8207699 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. Kovarik JM; Purba HS; Pongowski M; Gerbeau C; Humbert H; Mueller EA Pharmacotherapy; 1998; 18(6):1230-6. PubMed ID: 9855321 [TBL] [Abstract][Full Text] [Related]
8. Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar. Ortega I; Rodriguez M; Suarez E; Perez-Ruixo JJ; Calvo R Pharm Res; 2007 Jul; 24(7):1299-308. PubMed ID: 17380267 [TBL] [Abstract][Full Text] [Related]
9. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Drewe J; Ball HA; Beglinger C; Peng B; Kemmler A; Schächinger H; Haefeli WE Br J Clin Pharmacol; 2000 Sep; 50(3):237-46. PubMed ID: 10971308 [TBL] [Abstract][Full Text] [Related]
10. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Ritschel WA Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110 [TBL] [Abstract][Full Text] [Related]
11. Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. Binkhathlan Z; Hamdy DA; Brocks DR; Lavasanifar A Eur J Pharm Biopharm; 2010 Jun; 75(2):90-5. PubMed ID: 20332028 [TBL] [Abstract][Full Text] [Related]
12. Study on the peroral absorption of the endekapeptide cyclosporine A. Ritschel WA; Ritschel GB; Sabouni A; Wolochuk D; Schroeder T Methods Find Exp Clin Pharmacol; 1989 Apr; 11(4):281-7. PubMed ID: 2755275 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. Bullingham R; Monroe S; Nicholls A; Hale M J Clin Pharmacol; 1996 Apr; 36(4):315-24. PubMed ID: 8728345 [TBL] [Abstract][Full Text] [Related]
14. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. Choi SJ; Shin SC; Choi JS Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers. Piñeyro-López A; Piñeyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez-Silva M; Waksman N; E Salazar-Leal M; Luján-Rangel R Clin Ther; 2007 Sep; 29(9):2049-54. PubMed ID: 18035203 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of infusional valspodar. Ma MK; McLeod HL; Westervelt P; Fracasso PM J Clin Pharmacol; 2002 Apr; 42(4):412-8. PubMed ID: 11936566 [TBL] [Abstract][Full Text] [Related]
17. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Wahlberg J; Wilczek HE; Fauchald P; Nordal KP; Heaf JG; Olgaard K; Hansen JM; Lokkegaard H; Mueller EA; Kovarik JM Transplantation; 1995 Oct; 60(7):648-52. PubMed ID: 7570970 [TBL] [Abstract][Full Text] [Related]
18. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. Binkhathlan Z; Hamdy DA; Brocks DR; Lavasanifar A Xenobiotica; 2010 Jan; 40(1):55-61. PubMed ID: 19903013 [TBL] [Abstract][Full Text] [Related]
20. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? Ku YM; Min DI; Flanigan M J Clin Pharmacol; 1998 Oct; 38(10):959-65. PubMed ID: 9807978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]